1.Production, characterization, and clinical application of perchloric acid extract of M. bovis BCG (BCG I).
Journal of the Korean Pediatric Society 1992;35(8):1059-1065
No abstract available.
Mycobacterium bovis*
2.The Necessity of a Nationwide Surveillance System of Serious BCG Adverse Reactions.
Journal of Korean Medical Science 2019;34(1):e10-
No abstract available.
Mycobacterium bovis*
3.Differentiation between Mycobacterium bovis and Mycobacterium tuberculosis Infection.
Won Jung KOH ; Young Kil PARK ; Chang Ki KIM
Korean Journal of Medicine 2012;83(4):550-552
No abstract available.
Mycobacterium
;
Mycobacterium bovis
;
Mycobacterium tuberculosis
4.Effects of BCG infection on the multiplication of R.tsutsugamushi in the mouse.
Bok Soo LEE ; Yung Kwon HONG ; Chang Duk JUN ; In Jae KIM ; Hun Taek JUNG ; Suk Don PARK ; Ik Sang KIM ; Woo Hyun CHANG
Korean Journal of Infectious Diseases 1993;25(2):91-101
No abstract available.
Animals
;
Mice*
;
Mycobacterium bovis*
5.Two Cases of Eczematoid Reactions following BCG Vaccinations.
Jee Woong KIM ; Woo Seok CHOI ; Hyun Su PARK ; Jung Chul CHOI ; Sang Jai JANG
Korean Journal of Dermatology 2007;45(2):165-167
The adverse effects of BCG vaccination span diversely from systemic to local reactions. However, the adverse effects of BCG vaccination on the skin are rare and these can appear as non-specific or specific skin reactions. We experienced two cases of non-specific skin reaction, which occurred on a vaccine-injected site. Eczematous lesions with the clinical and pathological findings have not previously been report in the English dermatologic literature. Herein, we present two interesting cases of non-specific skin reactions from dermatological complications of BCG vaccination.
Mycobacterium bovis*
;
Skin
;
Vaccination*
6.PPD Conversion Rate and Complications According to the Different Time of BCG Vaccination.
Kyung Hyo KIM ; Seung Joo LEE ; Keun LEE
Journal of the Korean Pediatric Society 1987;30(5):487-490
No abstract available.
Mycobacterium bovis*
;
Vaccination*
7.The effectiveness of the antiidiotypic monoclonal antibody therapy conjugated to KLH and BCG in malignant melanoma.
Jeoung Won BAE ; Cheung Wung WHANG ; Sae Min KIM ; S FERRONE
Journal of the Korean Surgical Society 1993;44(3):322-333
No abstract available.
Melanoma*
;
Mycobacterium bovis*
8.The Significance of p53 and bcl-2 Protein Expression as Predictor of Recurrence after Intravesical BCG Therapy.
Korean Journal of Urology 2000;41(2):310-316
No abstract available.
Mycobacterium bovis*
;
Recurrence*
9.A Case of Granulomatous Prostatitis after Intravesical BCG Instillatio.
Dong Young KIM ; Jeong Kee LEE ; Yong Sul PARK ; Tae Hyo KIM ; Yong Soo LIM ; Hong Nang SHIM
Korean Journal of Urology 2000;41(7):901-903
No abstract available.
Mycobacterium bovis*
;
Prostatitis*
10.Pilot production of live, cryoprecipitate BCG (Im.BCG).
Journal of Preventive Medicine 1999;9(1):57-61
The live and cryoprecipitate BCG had been produced successfully at Nha Trang - Da Lat Institute of vaccine and biological substances (Im. BCG) of 37.5 mg/vial met standard of Ha Noi National Center for Vaccine and Biological substance control and WHO. Im.BCG met the standards of the sterillization and the safety. The live unit attained 2.6 +/- 0.54 x 108 per vial, the rate of thermal stability was 58.2 +/- 0.023, the dispension density was 1.22 +/- 0.119 and the additive huminity was 2.46 +/- 0.27%.
Mycobacterium bovis
;
vaccines
Result Analysis
Print
Save
E-mail